Cetuximab is an epidermal growth factor receptor inhibitor which has been recently focused
on the therapy of squamous cell carcinoma of the head and neck based on the nearly …

Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor
receptor. The role of cetuximab is paramount in several subsets of head and neck cancer. In …

The majority of the head and neck cancers are squamous cell carcinomas, which commonly
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …

Background and Objective: Cetuximab combined with radiotherapy or chemotherapy has
been used to treat head and neck cancer in recent years, but few reports are available in …

As EGFR is overexpressed in over 90% of all squamous cell cancers of the head and neck
(SCCHN) there is a strong rationale supporting Epidermal Growth Factor Receptor (EGFR) …

Context: Treatment outcome for locally advanced squamous cell carcinoma of the head and
neck is poor. Recently, anti-epidermal growth factor monoclonal antibodies, such as …

Squamous cell carcinoma of the head and neck (HNSCC) while curable in many cases with
surgery, radiation, and chemotherapy, remains a disease that is associated with significant …

Head and neck cancer is the sixth most common cancer worldwide. At present, globally
about 650,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) are …

Recently published evidence has shown an improvement in locoregional control and a
survival advantage in the treatment of squamous cell carcinomas of the head and neck …